Is the sector starting to bottom? It certainly does not feel like it as every gain is followed by more selling. No move higher seems to have any staying power. Positive starts to the day are sold by the end of the day. All that being said bottom and tops looks so clear in hindsight […]
October 29 Biotech Update
Surprisingly not any M&A (I say sarcastically). It is interesting, however, that there are some partnership deals and this makes me wonder if that is the new M&A. It is a relatively cheap way to get access to a particular asset with relatively lower risk especially if most of the biobucks are commercial. It is […]
October 17 Biotech Update
Yesterday was obviously a great day for the sector with everything higher and by a lot. It is not stunning to see some pullback from that move but if there is truly a reinvigorated sector, then you would want to see this red opening reverse into a green day to turn yesterday from a one-off […]
September 13th Biotech Update
We are finally getting a broad snap back rally but it needs to be more than a simple morning rally that is faded as the day goes along. If this rally is not built upon during the day, then odds are it simply reset the RSI and opened up a path to retest the bottom […]
August 24th biotech update
The snoozer of a week continues with the sector still chopping in its range. Perhaps next week we wake up a little but odds are we are stuck in this pattern until the fall conference season begins in September. 1. We will have some news this weekend with the PFE tafamidis data and while odds […]
August 22nd Biotech Update
Still not a ton of news and the sector moved higher with the market taking it a little further from the edge but still well within its range. I am still watching to see how the relatively performance in the sector plays out in that will we see large pharma continue to outperform followed by […]
August 13 Biotech Update
The chop continues and I suspect this week will be no different. There is not any news to start the week that would excite or disappoint, which means the previous trend (of no trend) is the path of least resistance. It is interesting that no one even talks about M&A anymore as that was supposed […]
August 2 Biotech Update
The sector continues to hold up in terms of price action relative to the broader market. If the market can at least stabilize, the sector has a good chance to eventually regain and perhaps break through recent highs. Obviously, all bets are off if the broader market collapses. My inclination is that the tech and […]
July 13 Biotech Update
While we are talking about small numbers and small difference, I would argue that it looks like large caps are finally starting to show some relative strength to SMID. I would argue that this is a better case to build a new breakout than one led by SMID as those moves are likely more driven […]
July 11 Biotech Update
Apparently my effect is now hitting the broader markets as they are pretty weak today. It could be more trade tensions with the Trump administration amping up the trade war rhetoric with China but I would not discount my impact. That being said I would not be looking for the sector to trade green in […]
April 12 Biotech Update
I am still convinced that the biggest macro risk for the market remains Syria. While there remains a chance that there is ultimately no attack, it seems that the past couple days has been a buildup of assets around Syria to allow for a more robust campaign. The final decision has not been made but […]
April 5 Biotech Update
The sector finally got its bounce and took some of the beaten down large caps with it. The sector (and market more generally) needs to follow through on this move and I do not mean a couple more hours but days of consolidation. A little back filling is fine but we cannot have another one […]
February 27 Biotech Update
So still a relatively slow news week. There are a couple of interesting tidbits that came out the past day that are useful to highlight, although nothing that would be particularly thesis changing. 1. The CLVS numbers appeas to be around consensus, although there were a couple of price target lowerings as the ramp seems […]
February 26 Biotech Update
A slow start to the week, although the sector does not seem bothered by the lack of news or M&A to start the week. There is some additional earnings this week but outside of potential data coming for a couple stocks, there does not seem a lot of imminent thesis changing news. 1. Today is […]
February 16 Biotech Update
There has been some interesting news to end the week. The market seems to have recovered its footing a little and this includes the sector. There is still some work to be done to repair the damage of the sell off but so far so good. 1. NBIX has been interesting. I thought it would […]
February 2 Biotech Update
It looks like the correction continues. Fundamental news does not seem to be matter a lot this week, which seems like typical price action during a correction. This does not seem sector specific and I doubt that it becomes anything more than a correction in a larger bull market but that does not mean it […]
January 31 Biotech Update
We had a nice little correction yesterday but while it was certainly a meaningful move compared to recent price action, it did not really remove any of the real fluff in the sector. That being said it could be enough to reset the “over bought” conditions and lead to a continuation of the rally. While […]
January 30 Biotech Update
The sector remains strong. The market has weakened a little but the sector was still holding on. If the broader market weakness continues, it will eventually drag down the sector but that has not happened yet. Of course, a bit of a pullback is well overdue and will happen eventually but the trigger and timing […]
January 25 Biotech Update
We are getting some biotech earnings but nothing that is dramatically thesis changing. We had a little consolidation yesterday and I would not be surprised to see it continue but the trend remains higher and suspect that we break into new highs in the first quarter (assuming at least a benign general market environment). 1. […]
December 15 Biotech Update
The question I keep asking myself is whether or not JPM really will be the positive catalyst that everyone is expecting (or really hoping for). We know that companies tend to save good news for JPM and good news should push stocks higher especially if they have been lagging. While I understand that logic, I […]
